SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today affirmed its commitment to re-acquire GRAIL, a healthcare company focused on multi-cancer early detection. “This acquisition is ...

Illumina (NASDAQ:ILMN) plans to divest cancer tester developer Grail after a U.S. Fifth Circuit Court of Appeal ruling on Friday. As Illumina (ILMN) previously stated, if it wasn't successful with ...

Battered by more than three years of opposition from authorities in the United States and Europe—most recently an unfavorable federal appeals court decision on Friday—Illumina said it will divest ...

WASHINGTON, June 5 (Reuters) - Illumina (ILMN.O), opens new tab on Monday filed an appeal against a Federal Trade Commission (FTC) order, demanding that it divest ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Grail was planning an IPO before ...

On June 3, 2024, Illumina’s (NASDAQ: ILMN, $109.82, Market Capitalization: $17.5 billion) board of directors approved the spin-off of its wholly owned subsidiary GRAIL, Inc. and shared the details on ...

U.S. antitrust regulators have ordered San Diego’s Illumina to unwind its $7 billion acquisition of early detection cancer screening outfit Grail — reversing a previous ruling by an administrative law ...